Trial result

Radiopharmaceuticals Just Got a Necessary No

Ovarian Cancer May Finally Have a Way to Drug p53

Lymphoma Is Testing How Far Chemo-Free Care Can Go

Myositis Finally Gets a Targeted Signal

Breast Cancer Immunotherapy Has a New Problem: Who Gets the Second Checkpoint?

Avexitide Phase 3 trial cuts post-bariatric hypoglycemia events by 55%

Small-Cell Lung Cancer Gets an ADC Signal With Teeth

Myeloma Gets an Accelerated Approval. The Endpoint Is the Politics.

ctDNA Is Becoming a Surveillance Policy, Not Just a Test
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.
